On Target Podcast

Megan Hall, senior vice president for global medical affairs at GRAIL, explains how her company's test works to detect early cancer and its tissue of origin.

Jack Meehan, co-founder and analyst at Operon Research, talks about the where the diagnostics industry is now and where he sees it heading.

Mirna Jarosz, CEO of LiquidCellDx, explains how her company's liquid biopsy captures information about the tumor microenvironment, providing critical treatment guidance.

Hamed Amini, CEO and co-founder of Hepta Bio, tells us how his company's liquid biopsy can diagnose liver fibrosis due to MASH, identifying patients who are treatment candidates.

Ajit Singh, CEO of Harbinger Health, explains how his company's diagnostic determines whether a patient with nonspecific clinical signs has cancer.

Mike Klein, CEO of Genomenon, explains how the company combines AI-powered technology with expert human curation to mine the global scientific literature for evidence describing genetic variants.

Bob Wassman, chief medical officer and executive vice president of clinical affairs at MARABio, explains how testing for maternal auto-antibodies can drive early autism diagnosis and treatment.

Suchi Saria, founder and CEO of Bayesian Health, tells us about her company's sepsis-detection system - and how to successfully bring such a system into the clinic.

Connie Lehman, founder and CEO of Clairity, shares how AI-driven insights can improve early detection, personalize screening, and ultimately change the future of breast-cancer care.

Madhuri Hegde, SVP and CSO of Revvity, discusses how her company leverages partnerships and broad expertise in both life sciences and diagnostics to solve patient problems.

Janet Woodcock, distinguished FDA veteran and past deputy commissioner of the agency, gives us her take on AI, companion diagnostics, drugs for rare diseases, and how to earn trust for new technology.

Dawn Mattoon, CEO of Mercy Bioanalytics, explains how her company is using extracellular vesicles to successfully diagnose early stage cancer.

Doug Biehn, President and CEO of Octave Biosciences, talks about the difference that a biomarker test can make in the management of multiple sclerosis.

Alec Ford, CEO of Karius, shares how genomics and AI are expanding what's possible in infectious disease diagnostics — and why getting the right answer faster can make all the difference for immunocompromised patients battling cancer and other serious conditions.

Irene Ghobrial, founder of Predicta Biosciences, explains how bringing whole-genome sequencing into the clinic is taking diagnosis and treatment of multiple myeloma and blood cancers to a new level of precision.

Alka Chaubey, CMO of Bionano Genomics, explains how optical genome mapping addresses the unmet needs of cytogenomics - and what it takes to get pathbreaking new technology into the clinic.

Susan Tousi, CEO of DELFI Diagnostics, shares how her company is using AI and fragmentomics to make liquid biopsy more accessible and cancer less deadly.

James Lu, co-founder and CEO of Helix, tells us what his company is doing to make genomics part of the standard portfolio of health-care data.

Julia Cheek, founder and CEO of Everlywell, shares how her company is working to change not only the way people access, use, and understand home tests, but the way home tests fit into the entire landscape of medicine.

Katherine Stueland, CEO of GeneDx, shares how her company is scaling whole-genome and exome sequencing for the diagnosis of rare diseases.